Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 250

1.

Emotional and behavior problems in adopted children - The role of early adversities and adoptive parents' regulation and behavior.

Hornfeck F, Bovenschen I, Heene S, Zimmermann J, Zwönitzer A, Kindler H.

Child Abuse Negl. 2019 Oct 10;98:104221. doi: 10.1016/j.chiabu.2019.104221. [Epub ahead of print]

PMID:
31606608
2.

Maintenance Olaparib for Metastatic Pancreatic Cancer. Reply.

Golan T, Locker GY, Kindler HL.

N Engl J Med. 2019 Oct 10;381(15):1492-1493. doi: 10.1056/NEJMc1911185. No abstract available.

PMID:
31597029
3.

Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.

Hammel P, Kindler HL, Reni M, Cutsem EV, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Joo S, Yoo HK, Patel N, Golan T.

Ann Oncol. 2019 Sep 28. pii: mdz406. doi: 10.1093/annonc/mdz406. [Epub ahead of print]

PMID:
31562758
4.

Clinical assessment of 5-fluorouracil/leucovorin, nab-paclitaxel, and irinotecan(FOLFIRABRAX) in untreated gastrointestinal cancer patients using UGT1A1 genotype-guided dosing.

Joshi S, Catenacci DVT, Karrison TG, Peterson JD, Zalupski MM, Sehdev A, Wade J, Sadiq A, Picozzi VJ, Amico A, Marsh R, Kozloff MF, Polite B, Kindler H, Sharma MR.

Clin Cancer Res. 2019 Sep 26. pii: clincanres.1483.2019. doi: 10.1158/1078-0432.CCR-19-1483. [Epub ahead of print]

PMID:
31558477
5.

EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach.

Nicholson AG, Sauter JL, Nowak AK, Kindler HL, Gill RR, Remy-Jardin M, Armato SG 3rd, Fernandez-Cuesta L, Bueno R, Alcala N, Foll M, Pass H, Attanoos R, Baas P, Beasley MB, Brcic L, Butnor KJ, Chirieac LR, Churg A, Courtiol P, Dacic S, De Perrot M, Frauenfelder T, Gibbs A, Hirsch FR, Hiroshima K, Husain A, Klebe S, Lantuejoul S, Moreira A, Opitz I, Perol M, Roden A, Roggli V, Scherpereel A, Tirode F, Tazelaar H, Travis WD, Tsao MS, van Schil P, Vignaud JM, Weynand B, Cree I, Rusch VW, Girard N, Galateau-Salle F.

J Thorac Oncol. 2019 Sep 20. pii: S1556-0864(19)33232-0. doi: 10.1016/j.jtho.2019.08.2506. [Epub ahead of print]

PMID:
31546041
6.

EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma.

Tan YC, Srivastava S, Won BM, Kanteti R, Arif Q, Husain AN, Li H, Vigneswaran WT, Pang KM, Kulkarni P, Sattler M, Vaidehi N, Mambetsariev I, Kindler HL, Wheeler DL, Salgia R.

Oncogenesis. 2019 Sep 4;8(9):49. doi: 10.1038/s41389-019-0159-6.

7.

Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting.

Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG 3rd, Francis RJ, Gomez DR, Dahlberg S, Rimner A, Simone CB 2nd, de Perrot M, Blumenthal G, Adjei AA, Bueno R, Harpole DH Jr, Hesdorffer M, Hirsch FR, Pass HI, Yorke E, Rosenzweig K, Burt B, Fennell DA, Lindwasser W, Malik S, Peikert T, Mansfield AS, Salgia R, Yang H, Rusch VW, Nowak AK.

J Thorac Oncol. 2019 Oct;14(10):1718-1731. doi: 10.1016/j.jtho.2019.08.012. Epub 2019 Aug 27.

PMID:
31470129
8.

Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial.

Wei AC, Ou FS, Shi Q, Carrero X, O'Reilly EM, Meyerhardt J, Wolff RA, Kindler HL, Evans DB, Deshpande V, Misdraji J, Tamm E, Sahani D, Moore M, Newman E, Merchant N, Berlin J, Goff LW, Pisters P, Posner MC.

Ann Surg Oncol. 2019 Aug 15. doi: 10.1245/s10434-019-07685-1. [Epub ahead of print]

PMID:
31418130
9.

Reply to K. Masuda et al.

Fennell DA, Taylor P, Gilligan D, Nakano T, Scherpereel A, Pavlakis N, van Meerbeeck JP, Aerts JGJV, Nowak AK, Kindler H, Baas P.

J Clin Oncol. 2019 Sep 1;37(25):2294-2295. doi: 10.1200/JCO.19.01208. Epub 2019 Jul 22. No abstract available.

PMID:
31329517
10.

Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma.

Hassan R, Alley E, Kindler H, Antonia S, Jahan T, Honarmand S, Nair N, Whiting CC, Enstrom A, Lemmens E, Tsujikawa T, Kumar S, Choe G, Thomas A, McDougall K, Murphy AL, Jaffee E, Coussens LM, Brockstedt DG.

Clin Cancer Res. 2019 Oct 1;25(19):5787-5798. doi: 10.1158/1078-0432.CCR-19-0070. Epub 2019 Jul 1.

PMID:
31263030
11.

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL.

N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387. Epub 2019 Jun 2.

PMID:
31157963
12.

Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study).

Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein P, Morse MA, Zeh HJ 3rd, Weekes C, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, Laheru D, Murphy A, Whiting C, Nair N, Enstrom A, Ferber S, Brockstedt DG, Jaffee EM.

Clin Cancer Res. 2019 Sep 15;25(18):5493-5502. doi: 10.1158/1078-0432.CCR-18-2992. Epub 2019 May 24.

PMID:
31126960
13.

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.

van Brummelen EMJ, Levchenko E, Dómine M, Fennell DA, Kindler HL, Viteri S, Gadgeel S, López PG, Kostorov V, Morgensztern D, Orlov S, Zauderer MG, Vansteenkiste JF, Baker-Neblett K, Vasquez J, Wang X, Bellovin DI, Schellens JHM, Yan L, Mitrica I, DeYoung MP, Trigo J.

Invest New Drugs. 2019 May 7. doi: 10.1007/s10637-019-00783-7. [Epub ahead of print]

PMID:
31065954
14.

Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.

Hassan R, Morrow B, Thomas A, Walsh T, Lee MK, Gulsuner S, Gadiraju M, Panou V, Gao S, Mian I, Khan J, Raffeld M, Patel S, Xi L, Wei JS, Hesdorffer M, Zhang J, Calzone K, Desai A, Padiernos E, Alewine C, Schrump DS, Steinberg SM, Kindler HL, King MC, Churpek JE.

Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):9008-9013. doi: 10.1073/pnas.1821510116. Epub 2019 Apr 11.

15.

An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).

Innocenti F, Jiang C, Sibley AB, Denning S, Etheridge AS, Watson D, Niedzwiecki D, Hatch AJ, Hurwitz HI, Nixon AB, Furukawa Y, Kubo M, Crona DJ, Kindler HL, McLeod HL, Ratain MJ, Owzar K.

Pharmacogenet Genomics. 2019 Aug;29(6):123-131. doi: 10.1097/FPC.0000000000000375.

PMID:
30889042
16.

Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.

Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, Pachter JA, Weaver DT, Scherpereel A, Pavlakis N, van Meerbeeck JP, Cedrés S, Nolan L, Kindler H, Aerts JGJV.

J Clin Oncol. 2019 Apr 1;37(10):790-798. doi: 10.1200/JCO.2018.79.0543. Epub 2019 Feb 20.

PMID:
30785827
17.

Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance).

Morales-Oyarvide V, Yuan C, Babic A, Zhang S, Niedzwiecki D, Brand-Miller JC, Sampson-Kent L, Ye X, Li Y, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Wu K, Willett WC, Giovannucci EL, Wolpin BM, Meyerhardt JA, Fuchs CS, Ng K.

J Natl Cancer Inst. 2019 Feb 1;111(2):170-179. doi: 10.1093/jnci/djy098.

18.

A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.

Sharma MR, Joshi SS, Karrison TG, Allen K, Suh G, Marsh R, Kozloff MF, Polite BN, Catenacci DVT, Kindler HL.

Cancer. 2019 May 15;125(10):1629-1636. doi: 10.1002/cncr.31938. Epub 2019 Jan 15.

PMID:
30645764
19.

Is the Brief Child Abuse Potential Inventory (BCAPI) a valid measure of child abuse potential among mothers and fathers of young children in Germany?

Liel C, Meinck F, Steinert JI, Kindler H, Lang K, Eickhorst A.

Child Abuse Negl. 2019 Feb;88:432-444. doi: 10.1016/j.chiabu.2018.11.008. Epub 2019 Jan 5.

20.

Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma.

Li F, Ahmad M, Qayyum F, Straus CM, MacMahon H, Kindler H, Armato SG 3rd.

Eur Radiol. 2019 Jun;29(6):2981-2988. doi: 10.1007/s00330-018-5887-z. Epub 2019 Jan 7.

PMID:
30617480
21.

A Glimmer of Hope for Pancreatic Cancer.

Kindler HL.

N Engl J Med. 2018 Dec 20;379(25):2463-2464. doi: 10.1056/NEJMe1813684. No abstract available.

PMID:
30575492
22.

Genetic variation determines VEGF-A plasma levels in cancer patients.

Innocenti F, Jiang C, Sibley AB, Etheridge AS, Hatch AJ, Denning S, Niedzwiecki D, Shterev ID, Lin J, Furukawa Y, Kubo M, Kindler HL, Auman JT, Venook AP, Hurwitz HI, McLeod HL, Ratain MJ, Gordan R, Nixon AB, Owzar K.

Sci Rep. 2018 Nov 5;8(1):16332. doi: 10.1038/s41598-018-34506-4.

23.

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.

Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sallé F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J; TCGA Research Network, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M.

Cancer Discov. 2018 Dec;8(12):1548-1565. doi: 10.1158/2159-8290.CD-18-0804. Epub 2018 Oct 15.

PMID:
30322867
24.

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM.

J Thorac Oncol. 2018 Nov;13(11):1655-1667. doi: 10.1016/j.jtho.2018.08.2036. Epub 2018 Sep 25.

PMID:
30266660
25.

Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors.

Romero-Calvo I, Weber CR, Ray M, Brown M, Kirby K, Nandi RK, Long TM, Sparrow SM, Ugolkov A, Qiang W, Zhang Y, Brunetti T, Kindler H, Segal JP, Rzhetsky A, Mazar AP, Buschmann MM, Weichselbaum R, Roggin K, White KP.

Mol Cancer Res. 2019 Jan;17(1):70-83. doi: 10.1158/1541-7786.MCR-18-0531. Epub 2018 Aug 31.

PMID:
30171177
26.

Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.

Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, Patel JD, Rose B, Zhang SR, Weatherly M, Nelakuditi V, Knight Johnson A, Helgeson M, Fischer D, Desai A, Sulai N, Ritterhouse L, Røe OD, Turaga KK, Huo D, Segal J, Kadri S, Li Z, Kindler HL, Churpek JE.

J Clin Oncol. 2018 Oct 1;36(28):2863-2871. doi: 10.1200/JCO.2018.78.5204. Epub 2018 Aug 16.

PMID:
30113886
27.

The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.

Innocenti F, Owzar K, Jiang C, Etheridge AS, Gordân R, Sibley AB, Mulkey F, Niedzwiecki D, Glubb D, Neel N, Talamonti MS, Bentrem DJ, Seiser E, Yeh JJ, Van Loon K, McLeod H, Ratain MJ, Kindler HL, Venook AP, Nakamura Y, Kubo M, Petersen GM, Bamlet WR, McWilliams RR.

PLoS One. 2018 Aug 14;13(8):e0202272. doi: 10.1371/journal.pone.0202272. eCollection 2018.

28.

Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance).

Guercio BJ, Zhang S, Niedzwiecki D, Li Y, Babic A, Morales-Oyarvide V, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Zoltick ES, Stampfer M, Ng K, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA, Fuchs CS.

PLoS One. 2018 Jul 19;13(7):e0199244. doi: 10.1371/journal.pone.0199244. eCollection 2018.

29.

Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study.

Gudmundsson E, Labby Z, Straus CM, Sensakovic WF, Li F, Rose B, Cunliffe A, Kindler HL, Armato SG 3rd.

Eur Radiol. 2019 Feb;29(2):682-688. doi: 10.1007/s00330-018-5533-9. Epub 2018 Jul 2.

PMID:
29967955
30.

Reply to D. de Fonseka et al.

Kindler HL, Rusch V, Bueno R, Ismaila N, Pass H, Sterman D, Hassan R.

J Clin Oncol. 2018 Sep 10;36(26):2746-2747. doi: 10.1200/JCO.2018.78.7333. Epub 2018 Jun 14. No abstract available.

PMID:
29902108
31.

Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).

Brown JC, Zhang S, Niedzwiecki D, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Li Y, Zhang X, Ng K, Willett WC, Giovannucci EL, Fuchs CS, Meyerhardt JA.

JNCI Cancer Spectr. 2018 Feb;2(2):pky017. doi: 10.1093/jncics/pky017. Epub 2018 May 30.

32.

Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial.

Van Blarigan EL, Fuchs CS, Niedzwiecki D, Zhang S, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Giovannucci EL, Ng K, Meyerhardt JA.

JAMA Oncol. 2018 Jun 1;4(6):783-790. doi: 10.1001/jamaoncol.2018.0126.

33.

The impact of changes in radiographic sarcopenia on overall survival in older adults undergoing different treatment pathways for pancreatic cancer.

Benjamin AJ, Buschmann MM, Zhang SQ, Wroblewski K, Kindler HL, Roggin KK, Dale W.

J Geriatr Oncol. 2018 Jul;9(4):367-372. doi: 10.1016/j.jgo.2018.03.002. Epub 2018 Mar 10.

PMID:
29534880
34.

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline Summary.

Kindler HL, Ismaila N, Hassan R.

J Oncol Pract. 2018 Apr;14(4):256-264. doi: 10.1200/JOP.17.00012. Epub 2018 Mar 8. No abstract available.

PMID:
29517955
35.

Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance).

Fadelu T, Zhang S, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson AB, Atienza DM, Messino M, Kindler HL, Venook A, Ogino S, Ng K, Wu K, Willett W, Giovannucci E, Meyerhardt J, Bao Y, Fuchs CS.

J Clin Oncol. 2018 Apr 10;36(11):1112-1120. doi: 10.1200/JCO.2017.75.5413. Epub 2018 Feb 28.

36.

Marine ω-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance).

Van Blarigan EL, Fuchs CS, Niedzwiecki D, Ye X, Zhang S, Song M, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Giovannucci EL, Meyerhardt JA.

Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):438-445. doi: 10.1158/1055-9965.EPI-17-0689. Epub 2018 Jan 22.

37.

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Kindler HL, Ismaila N, Armato SG 3rd, Bueno R, Hesdorffer M, Jahan T, Jones CM, Miettinen M, Pass H, Rimner A, Rusch V, Sterman D, Thomas A, Hassan R.

J Clin Oncol. 2018 May 1;36(13):1343-1373. doi: 10.1200/JCO.2017.76.6394. Epub 2018 Jan 18.

PMID:
29346042
38.

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.

O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, Kelsen DP.

Cancer. 2018 Apr 1;124(7):1374-1382. doi: 10.1002/cncr.31218. Epub 2018 Jan 16.

39.

Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.

Kanteti R, Mirzapoiazova T, Riehm JJ, Dhanasingh I, Mambetsariev B, Wang J, Kulkarni P, Kaushik G, Seshacharyulu P, Ponnusamy MP, Kindler HL, Nasser MW, Batra SK, Salgia R.

Cancer Biol Ther. 2018 Apr 3;19(4):316-327. doi: 10.1080/15384047.2017.1416937. Epub 2018 Feb 22.

40.

Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.

Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, Moore MJ, Kindler HL, Golan T, Segal A, Maynard H, Hollywood E, Moynahan M, Salo-Mullen EE, Do RKG, Chen AP, Yu KH, Tang LH, O'Reilly EM.

Eur J Cancer. 2018 Jan;89:19-26. doi: 10.1016/j.ejca.2017.11.004. Epub 2017 Dec 8.

PMID:
29223478
41.

Countering posttraumatic LHPA activation in refugee mothers and their infants.

Ullmann E, Bornstein SR, Lanzman RS, Kirschbaum C, Sierau S, Doehnert M, Zimmermann P, Kindler H, Schauer M, Ruf-Leuschner M, Fegert JM, von Klitzing K, Ziegenhain U.

Mol Psychiatry. 2018 Jan;23(1):2-5. doi: 10.1038/mp.2017.235. Epub 2017 Nov 14. No abstract available.

42.

Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study.

de W Marsh R, Talamonti MS, Baker MS, Posner M, Roggin K, Matthews J, Catenacci D, Kozloff M, Polite B, Britto M, Wang C, Kindler H.

J Surg Oncol. 2018 Mar;117(3):354-362. doi: 10.1002/jso.24872. Epub 2017 Oct 16.

43.

Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.

Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, Alpert L, Kwak H, Kindler H, Polite B, Sharma MR, Allen K, O'Day E, Lomnicki S, Maranto M, Kanteti R, Fitzpatrick C, Weber C, Setia N, Xiao SY, Hart J, Nagy RJ, Kim KM, Choi MG, Min BH, Nason KS, O'Keefe L, Watanabe M, Baba H, Lanman R, Agoston AT, Oh DJ, Dunford A, Thorner AR, Ducar MD, Wollison BM, Coleman HA, Ji Y, Posner MC, Roggin K, Turaga K, Chang P, Hogarth K, Siddiqui U, Gelrud A, Ha G, Freeman SS, Rhoades J, Reed S, Gydush G, Rotem D, Davison J, Imamura Y, Adalsteinsson V, Lee J, Bass AJ, Catenacci DV.

Cancer Discov. 2018 Jan;8(1):37-48. doi: 10.1158/2159-8290.CD-17-0395. Epub 2017 Oct 4.

44.

Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma.

Vigneswaran WT, Kircheva DY, Rodrigues AE, Watson S, Celauro AD, Rose B, Kindler HL, Husain AN.

World J Surg. 2018 Apr;42(4):1036-1045. doi: 10.1007/s00268-017-4264-4.

PMID:
28948332
45.

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

Maio M, Scherpereel A, Calabrò L, Aerts J, Cedres Perez S, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HL.

Lancet Oncol. 2017 Sep;18(9):1261-1273. doi: 10.1016/S1470-2045(17)30446-1. Epub 2017 Jul 17.

PMID:
28729154
46.

A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.

Wagner AJ, Kindler H, Gelderblom H, Schöffski P, Bauer S, Hohenberger P, Kopp HG, Lopez-Martin JA, Peeters M, Reichardt P, Qin A, Nippgen J, Ilaria RL, Rutkowski P.

Ann Oncol. 2017 Mar 1;28(3):541-546. doi: 10.1093/annonc/mdw659.

47.

Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance).

Fuchs MA, Yuan C, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Innocenti F, Warren RS, Bertagnolli MM, Ogino S, Giovannucci EL, Horvath E, Meyerhardt JA, Ng K.

Ann Oncol. 2017 Jun 1;28(6):1359-1367. doi: 10.1093/annonc/mdx109.

48.

Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.

Wang X, Wang X, Hodgson L, George SL, Sargent DJ, Foster NR, Ganti AK, Stinchcombe TE, Crawford J, Kratzke R, Adjei AA, Kindler HL, Vokes EE, Pang H.

Oncologist. 2017 Feb;22(2):189-198. doi: 10.1634/theoncologist.2016-0121. Epub 2017 Feb 10.

49.

Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.

Golan T, Sella T, O'Reilly EM, Katz MH, Epelbaum R, Kelsen DP, Borgida A, Maynard H, Kindler H, Friedmen E, Javle M, Gallinger S.

Br J Cancer. 2017 Mar 14;116(6):697-702. doi: 10.1038/bjc.2017.19. Epub 2017 Feb 9.

50.

The Challenge of Defining Treatment Standards for a Rare Disease: Malignant Peritoneal Mesothelioma.

Kindler HL.

J Oncol Pract. 2016 Oct;12(10):936-937. No abstract available.

PMID:
27858567

Supplemental Content

Loading ...
Support Center